168 related articles for article (PubMed ID: 27301775)
1. Optimizing adjuvant therapy and survivorship care of stage III colon cancer.
Loree JM; Cheung WY
Future Oncol; 2016 Sep; 12(17):2021-35. PubMed ID: 27301775
[TBL] [Abstract][Full Text] [Related]
2. New adjuvant therapy for colon cancer: justified hope or commercial hype.
Galanis E; Alberts SR; O'Connell MJ
Surg Oncol Clin N Am; 2000 Oct; 9(4):813-23; discussion 825-6. PubMed ID: 11008249
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
[TBL] [Abstract][Full Text] [Related]
4. A combined analysis of mismatch repair status and thymidylate synthase expression in stage II and III colon cancer.
Öhrling K; Karlberg M; Edler D; Hallström M; Ragnhammar P
Clin Colorectal Cancer; 2013 Jun; 12(2):128-35. PubMed ID: 23276521
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
Prescrire Int; 2011 Feb; 20(113):46-9. PubMed ID: 21488594
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adjuvant FOLFOX Chemotherapy Duration on Outcomes of Patients With Stage III Colon Cancer.
Kumar A; Peixoto RD; Kennecke HF; Renouf DJ; Lim HJ; Gill S; Speers CH; Cheung WY
Clin Colorectal Cancer; 2015 Dec; 14(4):262-8.e1. PubMed ID: 26123496
[TBL] [Abstract][Full Text] [Related]
7. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant and palliative anticancer treatment of colon carcinoma in 2004].
Medinger M; Steinbild S; Mross K
Praxis (Bern 1994); 2004 Sep; 93(40):1633-44. PubMed ID: 15495753
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy of colon cancer: current status and future directions.
Chung KY; Saltz LB
Cancer J; 2007; 13(3):192-7. PubMed ID: 17620769
[TBL] [Abstract][Full Text] [Related]
11. [Progression of adjuvant chemotherapy for colon cancer].
He YJ; Dong QM; Li YH
Ai Zheng; 2005 Dec; 24(12):1546-9. PubMed ID: 16351811
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.
Schmoll HJ; Tabernero J; Maroun J; de Braud F; Price T; Van Cutsem E; Hill M; Hoersch S; Rittweger K; Haller DG
J Clin Oncol; 2015 Nov; 33(32):3733-40. PubMed ID: 26324362
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis.
Tang M; Price TJ; Shapiro J; Gibbs P; Haller DG; Arnold D; Peeters M; Segelov E; Roy A; Tebbutt N; Pavlakis N; Karapetis C; Burge M
Expert Rev Anticancer Ther; 2018 Apr; 18(4):339-349. PubMed ID: 29478352
[TBL] [Abstract][Full Text] [Related]
14. Geographic variation and sociodemographic disparity in the use of oxaliplatin-containing chemotherapy in patients with stage III colon cancer.
Panchal JM; Lairson DR; Chan W; Du XL
Clin Colorectal Cancer; 2013 Jun; 12(2):113-21. PubMed ID: 23137529
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant colon cancer chemotherapy: where we are and where we'll go.
Lombardi L; Morelli F; Cinieri S; Santini D; Silvestris N; Fazio N; Orlando L; Tonini G; Colucci G; Maiello E
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S34-41. PubMed ID: 21129608
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
17. Practical outcome of adjuvant FOLFOX4 chemotherapy in elderly patients with stage III colon cancer: single-center study in Korea.
Kim JY; Kim YJ; Lee KW; Lee JS; Kim DW; Kang SB; Lee HS; Jang NY; Kim JS; Kim JH
Jpn J Clin Oncol; 2013 Feb; 43(2):132-8. PubMed ID: 23204187
[TBL] [Abstract][Full Text] [Related]
18. Current status of adjuvant therapy for colorectal cancer.
O'Connell MJ
Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
[TBL] [Abstract][Full Text] [Related]
19. The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?
Sobrero A; Grothey A; Iveson T; Labianca R; Yoshino T; Taieb J; Maughan T; Buyse M; André T; Meyerhardt J; Shields AF; Souglakos I; Douillard JY; Cervantes A
Ann Oncol; 2018 May; 29(5):1099-1107. PubMed ID: 29438451
[TBL] [Abstract][Full Text] [Related]
20. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]